Article

Another SABCS comes to a close

Author(s):

Well, another great year of SABCS has come to a close. Almost 8,000 people attended the meeting, with 58 percent coming from other parts of the world. Citizens from 94 countries were counted.This symposium has truly become one of the most significant international meetings for those interested in breast cancer. I hope that our coverage of this year's symposium has made you feel that you had a "courtside" seat to all of the important data presented here. I also hope you got to know the CURE team a little better. Now, I would appreciate hearing from you! What did you like, not like about this year's coverage? What can we do better next year? Is there something that really resonated with you? We want to hear it all so we can continue to be here for you at precisely the right time, the right place and in the right format.

Related Videos
Image of bald man.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Image of Dr. Salani.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Fakih.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
1 expert is featured in this series.
Related Content